Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024 Jan 2;13(1):21.
doi: 10.1167/tvst.13.1.21.

Efficacy of Morning Versus Evening Latanoprost/Timolol Fixed Combination for Open-Angle Glaucoma and Ocular Hypertension: A Randomized Clinical Trial

Hui Feng  1 , Dong Han  2 , Wensheng Lu  2 , Guangxian Tang  3 , Hengli Zhang  3 , Sujie Fan  4 , Aiguo Lv  4 , Jing Jiang  5 , Qing Zhang  1   6 , Ye Zhang  1 , Kai Cao  1   6 , Zhi Li  1 , Shuning Li  1
Affiliations
Randomized Controlled Trial

Efficacy of Morning Versus Evening Latanoprost/Timolol Fixed Combination for Open-Angle Glaucoma and Ocular Hypertension: A Randomized Clinical Trial

Hui Feng et al. Transl Vis Sci Technol. .

Abstract

Purpose: To compare the efficacy of morning and evening latanoprost/timolol fixed-combination (LTFC) dosing in patients with primary open-angle glaucoma (POAG) and ocular hypertension.

Methods: In this double-blind, randomized clinical trial, 63 untreated Chinese patients with POAG and ocular hypertension were enrolled. All patients received LTFC and were randomized (1:1) to group 1, morning (8 AM) dosing, or group 2, evening (8 PM) dosing. Vehicle drops were used in the morning or evening, accordingly, to preserve masking. Patients were treated for 4 weeks. Outcomes included mean reduction of the 24-hour intraocular pressure (IOP) and IOP fluctuation from baseline after a 4-week treatment.

Results: Fifty-six patients were included in the final analysis. In both groups, the posttreatment IOP values were significantly lower than those at baseline at each 24-hour measuring time point. A significant difference between the groups in IOP reduction from baseline was observed at the 9:30 AM time point (4.01 ± 2.62 vs. 2.42 ± 3.23 mm Hg, evening dosing versus morning dosing group; P = 0.048). Both groups showed decreased IOP fluctuation after treatment. However, the morning dosing group had a significantly greater decrease in diurnal IOP fluctuation than that of the evening dosing group (2.04 ± 2.32 mm Hg vs. 0.50 ± 1.70 mm Hg, respectively; P = 0.012).

Conclusions: Both morning and evening LTFC dosing can effectively reduce 24-hour IOP and IOP fluctuation. Morning dosing is more likely to effectively control diurnal IOP fluctuations.

Translational relevance: This multicenter, double-blind, randomized clinical trial generates robust evidence on the optimal LTFC dosing regimen to help clinical decision-making in the treatment of raised IOP.

PubMed Disclaimer

Conflict of interest statement

Disclosure: H. Feng, None; D. Han, None; W. Lu, None; G. Tang, None; H. Zhang, None; S. Fan, None; A. Lv, None; J. Jiang, None; Q. Zhang, None; Y. Zhang, None; K. Cao, None; Z. Li, None; S. Li, None

Figures

Figure 1.
Figure 1.
Patient flowchart.
Figure 2.
Figure 2.
The 24-hour patterns of mean IOP in the habitual body position at each time point.
See this image and copyright information in PMC

References

    1. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000; 130(4): 429–440. - PubMed
    1. Kass MA, Heuer DK, Higginbotham EJ.. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002; 120(6): 701–713; discussion 829–830. - PubMed
    1. Garway-Heath DF, Crabb DP, Bunce C, et al. .. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. Lancet. 2015; 385(9975): 1295–1304. - PubMed
    1. Leske MC, Heijl A, Hussein M.. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol. 2003; 121(1): 48–56. - PubMed
    1. Diestelhorst M, Larsson LI.. A 12-week, randomized, double-masked, multicenter study of the fixed combination of latanoprost and timolol in the evening versus the individual components. Ophthalmology. 2006; 113(1): 70–76. - PubMed

Publication types